• STAT+: Pharmalittle: Biogen R&D chief retiring amid controversy over Alzheimer's drug; Pfizer strikes deal for generic versions of its Covid pill

    21 days ago - By STAT

    Top of the morning to you, and a fine one it is. Crystal clear blue skies and a nippy breeze are enveloping the Pharmalot campus this morning, where the official mascot eagerly awaits the start of yet another play date and we are brewing needed cups of stimulation. Our choice today is peppermint mocha. Yum. We are, however, otherwise busy foraging for fascinating and juicy developments. So please keep us in mind when news crosses your own path. But we would be remiss if we did not remind you that a STAT Summit gets under way today with a cast of interesting folks. Meanwhile, here are a few...
    Read more ...

     

  • STAT+: Pfizer strikes a licensing deal with the Medicines Patent Pool for its Covid-19 pill

    21 days ago - By STAT

    Amid considerable anticipation over its Covid-19 pill, Pfizer reached a licensing agreement with the Medicines Patent Pool, which in turn can now strike deals with other manufacturers to provide versions of the drug to 95 low and middle-income countries.
    The agreement follows a similar arrangement with Merck concerning its own antiviral pill for combating the coronavirus. Notably, this also marks only the second time that a pharmaceutical company has struck a licensing deal with the Medicines Patent Pool - a public health organization backed by the United Nations - to widen access to a...
    Read more ...

     

  • Pfizer Will Allow Its Covid Pill to Be Made and Sold Cheaply in Poor Countries

    21 days ago - By New York Times

    The company announced a deal that could help significantly expand access to the Covid-19 treatment, but the agreement excludes a number of countries hit hard by the pandemic.
    Read more ...